Home > World > GBI Research Finds Asia-Pacific Asthma Market Hit $3.5 Billion in 2014; Will Reach $5.6 Billion by 2021
World

GBI Research Finds Asia-Pacific Asthma Market Hit $3.5 Billion in 2014; Will Reach $5.6 Billion by 2021

By March 11, 2016 at 1:40 am
health and beauty care Cambodia (Photo : Getty Images/ Hannah Reyes)

"Asthma Therapeutics in Asia-Pacific Markets to 2021,"  A new report from business intelligence provider GBI Research, states that the asthma therapeutics market in the Asia-Pacific (APAC) region will grow from $3.5 billion in 2014 to $5.6 billion by 2021, at a strong Compound Annual Growth Rate (CAGR) of 7.2%.

"As well as the increasing incidence of the disease, six costly biologics are set to enter the APAC asthma market which will push its value up considerably," analyst Aswini Nath said in a statement.

"These consist of GlaxoSmithKline's, mepolizumab, Teva's reslizumab, Chugai/Roche's lebrikizumab, Sanofi/Regeneron's dupilumab, and AstraZeneca's tralokinumab and benralizumab."

The primary driver of this considerable rise is the prevalence of asthma across the APAC countries, which include China, India, Australia, South Korea, and Japan. The condition is burgeoning due to aging populations and increases in air pollution, dust and pollen levels, which both cause and exacerbate asthma in children.

"The most advanced of these drugs is mepolizumab, which is currently at the Pre-registration stage in Japan, while the other five monoclonal antibodies (mAbs) are in Phase III development in the APAC region," Nath said.

"As the cost of these treatments is likely to be high in comparison with more established drugs, strong uptake could well increase the cost of treatment for asthma patients."

GBI Research also states that India has the highest number of asthma sufferers of the five APAC countries. In 2014, 53.6 million people were estimated to be living with the disease, which is approximately 52.4% of the total assessed Asia-Pacific prevalence. Japan, by contrast, was the largest market of the five APAC countries in 2014 at $1.8 billion, and will continue its lead to 2021, growing to $3 billion at a CAGR of 7.1%.

"As Japan is ranked only third of the five countries in terms of disease prevalence, this reflects the relatively high cost of drugs, and the country's readiness to adopt promising new molecules such as the IL-targeting mAbs," the analyst concludes.

Like Us on Facebook